Illumina HiSeq 2500 sequencing; Reduction of PRC2 activity supports survival of TNBC cancer cells to cytotoxic treatments
Reduction of PRC2 activity supports survival of TNBC cancer cells to cytotoxic treatments
G-2 cells were treated with CAF (312,5 ng/ml cyclophosphamide, 15,6 ng/ml doxorubicin and 312,5 ng/ml 5-FU) in 10 cm plates for 48 hours in biological triplicates. Total RNA was extracted from G-2 cells with Qiazol (Qiagen) following the manufacturer's recommendations.  mRNA sequencing libraries were generated with the NEXTflex™ Rapid Illumina Directional Kit according to the manufacturer's instructions. The size of the generated libraries was estimated on High Sensitivity DNA chip (Agilent) using a Bioanalyser 2100 (Agilent).
Experimental Factor: compound
vehicle